Press coverage about Coherus BioSciences (NASDAQ:CHRS) has trended somewhat positive this week, Accern Sentiment reports. The research firm identifies positive and negative news coverage by reviewing more than twenty million news and blog sources. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. Coherus BioSciences earned a coverage optimism score of 0.21 on Accern’s scale. Accern also assigned media headlines about the biotechnology company an impact score of 46.9247710049494 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the near term.
These are some of the media headlines that may have impacted Accern Sentiment Analysis’s scoring:
Several research firms have recently commented on CHRS. Citigroup lifted their price objective on Coherus BioSciences from $23.00 to $25.00 and gave the stock a “buy” rating in a report on Friday, March 9th. Maxim Group reiterated a “buy” rating and issued a $15.00 price objective (down previously from $20.00) on shares of Coherus BioSciences in a report on Friday, March 9th. BidaskClub upgraded Coherus BioSciences from a “sell” rating to a “hold” rating in a report on Wednesday, February 28th. ValuEngine downgraded Coherus BioSciences from a “sell” rating to a “strong sell” rating in a report on Friday, February 2nd. Finally, Zacks Investment Research downgraded Coherus BioSciences from a “buy” rating to a “hold” rating in a report on Tuesday, January 9th. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and eight have issued a buy rating to the company’s stock. Coherus BioSciences has a consensus rating of “Buy” and a consensus price target of $29.33.
Shares of NASDAQ:CHRS opened at $11.40 on Friday. Coherus BioSciences has a 1 year low of $8.05 and a 1 year high of $24.70. The stock has a market cap of $700.65, a P/E ratio of -2.54 and a beta of 3.40. The company has a current ratio of 5.12, a quick ratio of 5.12 and a debt-to-equity ratio of 3.33.
Coherus BioSciences (NASDAQ:CHRS) last announced its quarterly earnings results on Thursday, March 8th. The biotechnology company reported ($0.84) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.86) by $0.02. analysts expect that Coherus BioSciences will post -3 earnings per share for the current fiscal year.
COPYRIGHT VIOLATION NOTICE: “Coherus BioSciences (CHRS) Given Daily News Sentiment Score of 0.21” was first reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are viewing this news story on another domain, it was illegally copied and reposted in violation of U.S. and international copyright law. The legal version of this news story can be accessed at https://www.dispatchtribunal.com/2018/04/07/coherus-biosciences-chrs-given-daily-news-sentiment-score-of-0-21.html.
Coherus BioSciences Company Profile
Coherus BioSciences, Inc, a biosimilar company, develops and commercializes various therapeutic products worldwide. The company engages in the development of late-stage clinical products, including CHS-1701 pegfilgrastim biosimilar, a granulocyte colony-stimulating factor product candidate; CHS-1420 adalimumab biosimilar, an anti-tumor necrosis factor product candidate; and CHS-0214, an etanercept biosimilar for rheumatoid arthritis and psoriasis.
Receive News & Ratings for Coherus BioSciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Coherus BioSciences and related companies with MarketBeat.com's FREE daily email newsletter.